A Phase 1/2 Study of VLS-1488 in People With Various Types of Cancer


Full Title

A Phase I/II Study of VLS-1488 (An Oral KIF18A Inhibitor) in Subjects with Advanced Cancer


Researchers want to find the best dose of VLS-1488 to treat various types of advanced cancer. VLS-1488 blocks KIF18A, a protein that plays a role in the rapid growth of cancer cells. By blocking KIF18A, VLS-1488 may cause cancer cells to stop growing and die. VLS-1488 is taken orally (by mouth).

This study is for people with these cancers:

  • Ovarian cancer
  • Ovarian and uterine carcinosarcomas
  • Uterine serous carcinoma
  • Squamous cell non-small cell lung cancer
  • Triple-negative breast cancer
  • Gastric (stomach) cancer
  • Esophageal cancer
  • Colorectal cancer
  • Bladder cancer
  • Head and neck cancer

Who Can Join

To join this study, there are a few conditions. You must:

  • Have advanced cancer that cannot be successfully treated with standard therapies.
  • Have recovered from the serious side effects of prior treatments before taking VLS-1488.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information and to see if you can join this study, please call Dr. Claire Friedman’s office at 646-888-4593.




Phase I/II (phases 1 and 2 combined)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID